ReviewAbdominal radiology (New York)2026
Demystifying the imaging diagnoses of sclerosing cholangitis.
Review in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sclerosing cholangitis encompasses a group of conditions eventually leading to chronic cholestasis, and are characterized by inflammation, fibrosis, and segmental strictures of the intrahepatic and/or extrahepatic ducts. These can be either primary or secondary in origin. Primary sclerosing cholangitis (PSC) has no identifiable cause, while secondary sclerosing cholangitis (SSC) has various causes, producing similar chronic progressive changes in the biliary ducts. It is vital to differentiate between the two, as PSC is difficult to treat (with liver transplantation being the definitive treatment), while many causes of SSC are treatable, and even reversible. Therefore, it is imperative to exclude secondary causes of sclerosing cholangitis before establishing the diagnosis of PSC. While MRCP is the non-invasive imaging gold standard, ERCP, clinical correlation, and biopsy are frequently required to establish a definitive diagnosis. This review article presents a systematic approach to the imaging-based differential diagnoses of sclerosing cholangitis, integrating key clinical, laboratory, and radiological features.
Indexed as
Identifiers
41885964What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.